Skip Nav Destination
Close Modal
Update search
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Subjects
Journal
Article Type
Date
Availability
1-1 of 1
Keywords: Anti-VEGF therapies
Close
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Sort by
Journal Articles
Posterior Reversible Encephalopathy Syndrome Associated with Sorafenib and Successful Retreatment
Available to PurchaseSubject Area:
Further Areas
Journal:
Urologia Internationalis
Urol Int (2018) 100 (3): 357–360.
Published Online: 05 February 2016
... patients, the re-introduction of anti-VEGF therapies after PRES is feasible. Sorafenib is a small molecule for oral use that predominantly inhibits the serine/threonine Raf-1 kinase but also other tyrosine kinase receptors including VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-β, Flt3, and c-kit [ 16 ]. Sorafenib...
